Unlocking the Potential of Anti-TIGIT Therapy—Between Promise and Challenges
Mené sur 24 puis 49 patients atteints d'une tumeur solide de stade avancé (âges médians : 60 et 54 ans), cet essai non randomisé de phase IA/IB évalue la dose maximale tolérée du tiragolumab (un anticorps anti-TIGIT) seul et en combinaison avec l'atézolizumab
In the dynamic realm of immuno-oncology, breakthroughs are continually forged, yet challenges endure. The laudable success of immune checkpoint inhibitors such as anti–programmed cell death 1 protein (PD-1)/programmed cell death 1 ligand 1 (PD-L1), while transforming therapeutic landscapes, has yet to reach its full potential across all patient populations. The advent of anti–T-cell immunoreceptor with Ig and ITIM domains (TIGIT) therapies highlights this ongoing innovation, though the definitive evaluation of their clinical efficacy, particularly in conjunction with anti–PD-1, awaits further investigation.
JAMA Oncology , éditorial, 2022